Blaine Davis - 02 Jan 2026 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Chief Financial Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Blaine Davis
Issuer symbol
RNAC
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:18:46 UTC
Previous filing
07 Jan 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Blaine Chief Financial Officer C/O CARTESIAN THERAPEUTICS, INC., 7495 NEW HORIZON WAY, FREDERICK /s/ Matthew Bartholomae, Attorney-in-Fact for Blaine Davis 06 Jan 2026 0001802188

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +37,000 +39% $0.000000 131,811 02 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Employee Stock Option (right to buy) Award $0 +109,000 $0.000000 109,000 02 Jan 2026 Common Stock 109,000 $6.76 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.
F2 This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.